Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of therapy to strengthen the
immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can
prolong the time between the start of treatment and disease progression, decrease tumor size,
as well as determine if the combination therapy is safer and less toxic than the standard
treatment for renal cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System